Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate

Seminars in Nuclear Medicine

Volumn 31, Issue 1, 2001, Pages 28-49

  Blake, Glen M ^a   Park Holohan, So Jin ^a   Cook, Gary J R ^a   Fogelman, Ignac ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE 18; MEDRONATE TECHNETIUM TC 99M; TRACER;

ARTICLE; BLOOD FLOW; BONE DEVELOPMENT; BONE SCINTISCANNING; BONE TURNOVER; DIAGNOSTIC PROCEDURE; DRUG HALF LIFE; HUMAN; INTERMETHOD COMPARISON; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE DIAGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKELETON;

EID: 0035182487     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2001.18742     Document Type: Article

References (140)

1. The bone organ system: Form and function
2. Anatomy and ultrastructure of bone
3. Evolution of lumbar bone mineral content during adolescence and adulthood: A longitudinal study in 395 healthy females 10-24 years of age and 206 premenopausal women
4. The differing tempo of growth in bone size, mass, and density is region-specific
5. Rates of growth and loss of bone mineral in the spine and femoral neck in white females
6. Consensus Development Conference: Diagnosis, prophylaxis and treatment of osteoporosis
7. Biochemical markers of bone turnover
8. Measurements of biochemical markers: Methods and limitations
9. Clinical applications of biochemical markers of bone metabolism
10. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment
11. A single measurement of biochemical markers of bone turnover has limited utility in the individual person
12. Bone biopsy and histomorphometry in clinical practice
13. Clinical applications of bone densitometry
14. Technical principles of dual energy X-ray absorptiometry
15. Eastell R: Treatment of postmenopausal osteoporosis
16. Interpretation of bone densitometry studies
17. Critical analysis of methods for analysing human calcium kinetics
18. Use of calcium tracers and biomarkers to determine calcium kinetics and bone turnover
19. Alkaline earth metabolism in adult man
20. Technetium-99m-methylene disphosphonate - A superior agent for skeletal imaging: Comparison with other technetium complexes
21. 18F-fluoride for bone imaging
22. Bone turnover in osteoporosis
23. Bisphosphonates: A review of their pharmacokinetics properties
24. Radiopharmaceuticals for bone scanning
25. Bisphosphonates: From the laboratory to the clinic and back again
26. Bone scanning: Radionuclidic reaction mechanisms
27. 99mTc-labeled phosphate and phosphonate agents for skeletal imaging
28. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo
29. Paget's disease of bone
30. The hypercalcaemia of malignancy: Pathogenesis and treatment
31. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
32. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up
33. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
34. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
35. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lyric bone metastases
36. The palliative management of skeletal metastases in prostate cancer: Use of bone-seeking radionuclides and bisphosphonates
37. Studies on diphosphonate kinetics. Part I: Evaluation of plasma elimination curves during 24 h
38. Studies on diphosphonate kinetics. Part II: Whole body bone uptake rate during constant infusion - A refined index of bone metabolism
39. Chromium-51 EDTA/technetium-99m-MDP plasma ratio to measure total skeletal function
40. Intake and metabolism of fluoride
41. Anatomy of body water and electrolytes
42. Extracellular water measurements: Organ tracer kinetics of bromide and sucrose in rats and man
43. The measurement of the extracellular fluid volume with radioactive bromine
44. Halide transport in red blood cells
45. 18F
46. 18F in rabbit bone
47. Evaluation of the skeletal kinetics of fluorine- 18-fluoride ion with PET
48. Renal clearance of fluoride
49. Distribution, migration and binding of whole blood fluoride evaluated with radiofluoride
50. Electrophoretic mobility of serum fluoride
51. Fluoride renal clearance: A pH-dependent event
52. Fluoride bioavailability after intravenous and oral administration: Importance of renal clearance and urine flow
53. Renal clearance of fluoride in a steady state condition in man: Influence of urinary flow and pH changes by diet
54. Fluoride pharmacokinetics: Its implications in the fluoride treatment of osteoporosis
55. The use of whole-body retention of Tc-99m disphosphonate in the diagnosis of metabolic bone disease
56. Skeletal uptake of disphosphonate. Method for prediction of postmenopausal osteoporosis
57. Estimation of skeletal involvement in primary hyperparathyroidism
58. Age-related alterations in skeletal metabolism - 24-hr whole-body retention of disphosphonate in 250 normal subjects: Concise communication
59. Kinetics of technetium-99m-tinmethylene-diphosphonate in normal subjects and pathological conditions: A simple index of bone metabolism
60. Assessment of skeletal uptake of Tc-99m disphosphonate over a five-day period
61. Accuracy of 24-h whole-body (skeletal) retention of diphosphonate measurements
62. Measurement of 24-hour whole-body retention of Tc- 99m HEDP by a gamma camera
63. Urinary 99m-Tc-diphosphonate excretion as a simple method to quantify bone metabolism
64. Determination of bone turnover by urinary excretion of 99m-Tc-MDP
65. 99mTc-MDP retention in osteoporosis: Relationship to other indices of bone cell activity and response to calcium and vitamin D therapy
66. Whole-body counting
67. Relative distribution of disphosphonate between bone and soft tissue at 4 and 24 hours: Concise communication
68. The short-term fixation of radiopharmaceuticals in bone
69. 99mTc-diphosphonate uptake mechanism on bone
70. A comparison of skeletal uptakes of three diphosphonates by whole-body retention: Concise communication
71. Whole body retention of 99m-Tc-disphosphonate. Relation to biochemical indices of bone turnover and to total body calcium
72. GFR-corrected 24-hour whole body retention of diphosphonate: An improved index of bone metabolism
73. Biphosphonate whole body retention test: Relations to bone mineralisation rate, renal function and metabolic bone disorders
74. 99mTcmethylene-diphosphonate in the assessment of bone formation. Methodological evaluation, clinical applications and comparison with serum alkaline phosphatase and serum osteocalcin
75. 18F]fluoride kinetics in humans
76. Studies of skeletal tracer kinetics: II. Evaluation of a five-compartment model of [18F]fluoride kinetics in rats
77. Studies of skeletal tracer kinetics. III. Tc-99m(Sn)-methylene diphosphonate uptake in the canine tibia as a function of blood flow
78. Studies of skeletal tracer kinetics IV. Optimum time delay for Tc-99m(Sn) methylene disphosphonate bone imaging
79. Studies in skeletal tracer kinetics. V. Computer-simulated Tc-99m(Sn)methylene diphosphonate bone scan changes in certain systemic disorders
80. 85Sr
81. Fluid spaces in the canine tibia
82. An analytical solution set for a four-compartment mixed mammillary/catenary model
83. Skeletal blood flow: Implications for bonescan interpretation
84. Clearance kinetics of solutes used to measure glomerular filtration rate
85. Quantitation of Tc 99m MDP retention during routine bone scanning
86. 99mTc-DTPA: Comparison of plasma clearance techniques
87. Body surface area correction in single-sample methods of glomerular filtration rate estimation
88. Diphosphonate space: A useful quantitative index of disease activity in patients undergoing HMDP treatment or Paget's disease
89. Bisphosphonate space measurement in Paget's disease of bone treated with APD
90. The clinical measurement of skeletal blood flow
91. 85Sr in the skeleton
92. A new method for calculating the accretion rate of bone calcium and some observations on the suitability of strontium- 85 as a tracer for bone calcium
93. A new tracer method for the calculation of bone formation and breakdown in osteoporosis and other generalized skeletal disorders
94. Arterio-venous concentration difference of [51Cr]EDTA after a single injection in man. Significance of renal function and local blood flow
95. Skeletal blood flow, iliac histomorphometry, and strontium kinetics in osteoporosis: A relationship between bone blood flow and corrected apposition rate
96. Strontium-89 radionuclide therapy: A dosimetric study using impulse response function analysis
97. 18F]fluoride ion in renal osteodystrophy: Correlation with bone histomorphometry
98. 18F]fluoride ion and dynamic positron emission tomography
99. Fluoride kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET
100. 18F]fluoride ion PET in porcine vertebrae
101. 18F-fluoride positron emission tomography in postmenopausal women
102. The role of positron emission tomography in skeletal disease
103. Post-mortem migration of bone-seeking radionuclides in the rat and rabbit and its effect on estimates of bone uptake
104. A new method of assessing Tc-99m-MDP bone uptake from a bone scan image: Quantitative measurement of radioactivity in global skeletal region of interest
105. Tc-99m-MDP global skeletal uptake and markers of bone metabolism in patients with bone disease
106. Age-related changes in the global skeletal uptake of technetium- 99m methylene disphosphonate in healthy women
107. Age-related change of technetium-99m-HMDP distribution in the skeleton
108. Quantification of diphosphonate uptake based on conventional bone scanning
109. Quantitative bone scintigraphy using SPECT
110. A practical SPECT technique for quantitation of drug delivery to human tumors and organ absorbed radiation dose
111. In vivo SPECT quantitation of bone metabolism in hyperparathyroidism and thyrotoxicosis
112. Bone turnover in cortical and trabecular bone in normal women and in women with osteoporosis
113. Quantitative single-photon emission computed tomography: Basics and clinical considerations
114. Bone SPECT of the spine: A comparison of attenuation correction techniques
115. Bone blood flow and extraction ratios: Microspheres and bone seekers
116. Fluid space in bone
117. 99mTc-methylene diphosphonate
118. The importance of endothelium and interstitial fluid in nuclear medicine
119. Transport of potassium-42 from blood to tissue in isolated mammalian skeletal muscles
120. The mechanism of ion transfer in bone
121. Limitations of radioactive microspheres as tracers for bone blood flow and extraction ratio studies
122. Invalidity of single-passage measurements of the extraction of bone-seeking tracers in rats and rabbits
123. 18F in rabbit bone
124. Transcapillary exchange and retention of fluoride, strontium, EDTA sucrose and anitipyrine in blood
125. 99mTc-methylene diphosphonate as a function of bone blood flow
126. Localization of technetium-99m methylene diphosphonate in bone using microautoradiography
127. 99mTcpolyphosphate: Histological localization in human femurs by autoradiography
128. Skeletal uptake of pyrophosphate labeled with technetium-95m and technetium-96 as evaluated by autoradiography
129. Bone blood flow: Regional variation with skeletal maturation
130. Blood flow and tracer uptake in normal and abnormal canine bone: Comparisons with Sr-85 microspheres, Kr-81m, and Tc-99m MDP
131. Comparative evaluation of three diphosphonates: In vitro adsorption (C-14 labeled) and in vivo osteogenic uptake (Tc-99m complexed)
132. 99mTc-MDP
133. 99mTc-pertechnetate
134. 99mTc complex to bone
135. 99Tc
136. Fluoride effects on bone crystals
137. Topographical distribution of fluoride in iliac bone of a fluoride treated osteoporotic patient
138. The chemical dynamics of bone mineral
139. PET instrumentation: What are the limits?